Genomes and Genes
hiv envelope protein gp41
Summary: Transmembrane envelope protein of the HUMAN IMMUNODEFICIENCY VIRUS which is encoded by the HIV env gene. It has a molecular weight of 41,000 and is glycosylated. The N-terminal part of gp41 is thought to be involved in CELL FUSION with the CD4 ANTIGENS of T4 LYMPHOCYTES, leading to syncytial formation. Gp41 is one of the most common HIV antigens detected by IMMUNOBLOTTING.
Publications226 found, 100 shown here
- Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine targetLaura M Walker
Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, Scripps Research Institute, La Jolla, CA 92037, USA
Science 326:285-9. 2009..The results provide a framework for the design of new vaccine candidates for the elicitation of bNAb responses...
- Antibody neutralization and escape by HIV-1Xiping Wei
Howard Hughes Medical Institute, University of Alabama at Birmingham, 720 South 20th Street, Kaul 816, Birmingham, Alabama 35294 0024, USA
Nature 422:307-12. 2003..The evolving glycan shield thus represents a new mechanism contributing to HIV-1 persistence in the face of an evolving antibody repertoire...
- Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapyXiping Wei
Howard Hughes Medical Institute, Department of Medicine, University of Alabama at Birmingham, 35294, USA
Antimicrob Agents Chemother 46:1896-905. 2002..These findings provide the first evidence for the rapid emergence of clinical resistance to a novel class of HIV-1 entry inhibitors and may be relevant to future treatment strategies involving these agents...
- Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individualsJohannes F Scheid
Laboratory of Molecular Immunology, The Rockefeller University, New York, New York 10065, USA
Nature 458:636-40. 2009..Thus, the IgG memory B-cell compartment in the selected group of patients with broad serum neutralizing activity to HIV is comprised of multiple clonal responses with neutralizing activity directed against several epitopes on gp120...
- Elicitation of structure-specific antibodies by epitope scaffoldsGilad Ofek
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
Proc Natl Acad Sci U S A 107:17880-7. 2010..Epitope scaffolds thus provide a means to elicit antibodies that recognize a predetermined target shape and sequence, even if that shape is transient in nature, and a means by which to dissect factors influencing such elicitation...
- Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individualsYuxing Li
Vaccine Research Center, NIAID, NIH, Bethesda, Maryland 20892 3005, USA
J Virol 83:1045-59. 2009..These data allow a more detailed understanding of the humoral responses to the HIV-1 Env protein and provide insights regarding the most relevant targets for HIV-1 vaccine design...
- Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobilityMarie Pancera
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
Proc Natl Acad Sci U S A 107:1166-71. 2010..A "layered" gp120 architecture thus allows movement among alternative glycoprotein conformations required for virus entry and immune evasion, whereas a beta-sandwich clamp maintains gp120-gp41 interaction and regulates gp41 transitions...
- Broad and potent neutralization of HIV-1 by a gp41-specific human antibodyJinghe Huang
HIV Specific Immunity Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
Nature 491:406-12. 2012..The highly conserved MPER is a target of potent, non-self-reactive neutralizing antibodies, suggesting that HIV-1 vaccines should aim to induce antibodies to this region of HIV-1 envelope glycoprotein...
- Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodiesBarton F Haynes
Duke University School of Medicine, Durham, NC 27710, USA
Science 308:1906-8. 2005..These results may have important implications for generating effective neutralizing antibody responses by using HIV-1 vaccines...
- Subunit organization of the membrane-bound HIV-1 envelope glycoprotein trimerYoudong Mao
Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts, USA
Nat Struct Mol Biol 19:893-9. 2012..The cage-like architecture, which is unique among characterized viral envelope proteins, restricts antibody access, reflecting requirements imposed by HIV-1 persistence in the host...
- A mutation in the human immunodeficiency virus type 1 Gag protein destabilizes the interaction of the envelope protein subunits gp120 and gp41Melody R Davis
Department of Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN 37232 2363, USA
J Virol 80:2405-17. 2006..Our results suggest that an altered interaction between the MA domain of Gag and the gp41 cytoplasmic tail leads to dissociation of gp120 from gp41 during HIV-1 particle assembly, thus resulting in impaired fusion and infectivity...
- HIV enters cells via endocytosis and dynamin-dependent fusion with endosomesKosuke Miyauchi
Institute of Human Virology and Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
Cell 137:433-44. 2009..These findings imply that HIV-1 infects cells via endocytosis and envelope glycoprotein- and dynamin-dependent fusion with intracellular compartments...
- Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-LAnn J Hessell
Department of Immunology and Microbial Science and the International AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, 10550 N Torrey Pines Road, La Jolla, CA 92037, USA
J Virol 84:1302-13. 2010..The study confirms the protective potential of 2F5 and 4E10 and supports emphasis on HIV immunogen design based on the MPER region of gp41...
- Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitopeGilad Ofek
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Instiutes of Health, Bethesda, MD 20892, USA
J Virol 78:10724-37. 2004..Based on these structural and biochemical results, immunization strategies for eliciting 2F5- and 4E10-like broadly neutralizing anti-HIV-1 antibodies are proposed...
- Entry inhibitors in the treatment of HIV-1 infectionJohn C Tilton
Department of Microbiology, University of Pennsylvania, 301C Johnson Pavilion, 3610 Hamilton Walk, Philadelphia, PA 19104, United States
Antiviral Res 85:91-100. 2010..This article forms part of a special issue of Antiviral Research marking the 25th anniversary of antiretroviral drug discovery and development, Vol 85, issue 1, 2010...
- MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1Claudia R Ruprecht
Institute of Medical Virology, University Hospital Zurich, Switzerland
J Exp Med 208:439-54. 2011....
- Enhanced HIV-1 neutralization by antibody heteroligationHugo Mouquet
Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA
Proc Natl Acad Sci U S A 109:875-80. 2012..Heterotypic bivalent binding enhanced neutralization compared with the parental antibodies. We conclude that antibody recognition and viral neutralization of HIV can be improved by heteroligation...
- Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regionsVictor Buzon
Unit of Virus Host Cell Interactions UMI 3265, Université Joseph Fourier EMBL CNRS, Grenoble, France
PLoS Pathog 6:e1000880. 2010....
- Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sortingLynn Morris
Duke Human Vaccine Institute and Departments of Medicine, Surgery and Immunology, Duke University School of Medicine, Durham, North Carolina, United States of America
PLoS ONE 6:e23532. 2011..These data indicate that there are multiple immunogenic targets in the C-terminus of the MPER of HIV-1 gp41 envelope and suggests that gp41 neutralizing epitopes may interact with a restricted set of naive B cells during HIV-1 infection...
- Antibody mechanics on a membrane-bound HIV segment essential for GP41-targeted viral neutralizationMikyung Kim
Laboratory of Immunobiology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
Nat Struct Mol Biol 18:1235-43. 2011..Hence, target neutralization through this lipid-embedded viral segment places stringent requirements on the plasticity of the antibody combining site...
- Topological layers in the HIV-1 gp120 inner domain regulate gp41 interaction and CD4-triggered conformational transitionsAndres Finzi
Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Department of Pathology, Division of AIDS, Harvard Medical School, Boston, MA 02115, USA
Mol Cell 37:656-67. 2010..Thus, despite lack of contact with CD4, the gp120 inner-domain layers govern CD4 triggering by participating in conformational transitions within gp120 and regulating the interaction with gp41...
- Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated stateHillel Haim
Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Division of AIDS, Harvard Medical School, Boston, MA, USA
PLoS Pathog 5:e1000360. 2009..This novel strategy for inhibition may be generally applicable to high-potential-energy viral entry machines that are normally activated by receptor binding...
- Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 bindingQ J Sattentau
Academic Department of Genito Urinary Medicine, University College and Middlesex School of Medicine, London, United Kingdom
J Exp Med 174:407-15. 1991..We propose that these events occurring after CD4 binding are integral components of the membrane fusion reaction between HIV or HIV-infected cells and CD4+ cells...
- N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusionShibo Jiang
Lindsley F Kimball Research Institute, New York Blood Center, 310 E 67th St, New York, NY 10021, USA
Antimicrob Agents Chemother 48:4349-59. 2004..Therefore, NB-2 and NB-64 can be used as lead compounds toward designing and developing more potent small molecule HIV-1 fusion inhibitors targeting gp41...
- Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virusJohn J Dwyer
Trimeris Inc, 3500 Paramount Parkway, Morrisville, NC 27560, USA
Proc Natl Acad Sci U S A 104:12772-7. 2007..The potent antiviral activity against resistant viruses, the difficulty in generating resistant virus, and the extended half-life in vivo make this class of fusion inhibitor peptide attractive for further development...
- Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodiesJames M Binley
IMM2, Department of Immunology, The Scripps Research Institute, 10550 N Torrey Pines Rd, La Jolla, CA 92037, USA
J Virol 78:13232-52. 2004..As well as the significance for vaccine design, our data have implications for passive-immunization studies in countries where clade C viruses are common, given that only MAbs b12 and 4E10 were effective against viruses from this clade...
- HIV vaccine design and the neutralizing antibody problemDennis R Burton
Departments of Immunology and Molecular Biology, Scripps Research Institute, La Jolla, California, USA
Nat Immunol 5:233-6. 2004
- Induction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41S Moses Dennison
Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America
PLoS ONE 6:e27824. 2011..Nonetheless, the Env-liposome prime-boost immunization strategy induced antibodies that recognized a gp41 fusion intermediate protein and was successful in focusing the antibody response to the desired epitope...
- Dissociation of gp120 from HIV-1 virions induced by soluble CD4J P Moore
Chester Beatty Laboratories, Institute of Cancer Research, London, United Kingdom
Science 250:1139-42. 1990..This may represent the initial stage in virus-cell and cell-cell fusion. Shedding of gp120 from virions induced by sCD4 may also contribute to the mechanism by which these soluble receptor molecules neutralize HIV-1...
- Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactionsErin M Scherer
Department of Immunology, University of Washington, Seattle, WA 98195, USA
Proc Natl Acad Sci U S A 107:1529-34. 2010....
- Stable docking of neutralizing human immunodeficiency virus type 1 gp41 membrane-proximal external region monoclonal antibodies 2F5 and 4E10 is dependent on the membrane immersion depth of their epitope regionsS Moses Dennison
Human Vaccine Institute, Department of Medicine, Duke University School of Medicine, Durham, North Carolina 27710, USA
J Virol 83:10211-23. 2009..These data have important implications for the design and use of peptide-liposome conjugates as immunogens for the induction of MPER-neutralizing antibodies...
- HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membraneZhen Yu J Sun
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA
Immunity 28:52-63. 2008....
- HIV-1 gp41 fusogenic function triggers autophagy in uninfected cellsMelanie Denizot
CPBS, UM1, UM2, CNRS, Institut de Biologie, Montpellier, France
Autophagy 4:998-1008. 2008....
- Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining regionGilad Ofek
Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, Maryland 20892, USA
J Virol 84:2955-62. 2010..Together, the results provide a more complete understanding of the 2F5 mechanism of HIV-1 neutralization and indicate ways to enhance the potency of MPER-directed antibodies...
- Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibodyP D Kwong
Department of Biochemistry and Molecular Biophysics, Columbia University, New York, New York 10032, USA
Nature 393:648-59. 1998..Our results provide a framework for understanding the complex biology of HIV entry into cells and should guide efforts to intervene...
- Tail-interacting protein TIP47 is a connector between Gag and Env and is required for Env incorporation into HIV-1 virionsSandra Lopez-Verges
Institut Cochin, Département Maladies Infectieuses, 27 rue du Faubourg Saint Jacques, F 75014 Paris, France
Proc Natl Acad Sci U S A 103:14947-52. 2006....
- The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine designMarinieve Montero
Department of Molecular Biology and Chemistry, Simon Fraser University, 8888 University Drive, Burnaby V5A 1S6, British Columbia, Canada
Microbiol Mol Biol Rev 72:54-84, table of contents. 2008..In addition, emerging approaches to vaccine design are presented...
- Protein design of an HIV-1 entry inhibitorM J Root
Howard Hughes Medical Institute, Whitehead Institute for Biomedical Research, Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02142, USA
Science 291:884-8. 2001..The inhibitory activity of 5-Helix also suggests a strategy for generating an HIV-1 neutralizing antibody response that targets the carboxyl-terminal region of the gp41 ectodomain...
- Model for the structure of the HIV gp41 ectodomain: insight into the intermolecular interactions of the gp41 loopM Caffrey
Department of Biochemistry and Molecular Biology, University of Illinois at Chicago, Chicago, IL 60612, USA
Biochim Biophys Acta 1536:116-22. 2001..17 (1998) 4572--4584). The resulting model presents the first structural information for the HIV gp41 loop, which has been implicated to play a direct role in binding to gp120 and C1q of the complement system...
- A trimeric structural subdomain of the HIV-1 transmembrane glycoproteinM Lu
Howard Hughes Medical Institute, Whitehead Institute for Biomedical Research, Department of Biology, Massachusetts Institute of Technology, Cambridge 02142, USA
J Biomol Struct Dyn 15:465-71. 1997..Our results also provide strong support for the notion that short peptides can form unique, cooperatively folded subdomains, in which elements of secondary structure are stabilized by native-like tertiary interactions...
- Human immunodeficiency virus type 1 Env with an intersubunit disulfide bond engages coreceptors but requires bond reduction after engagement to induce fusionL G Abrahamyan
Department of Molecular Biophysics and Physiology, Rush Medical College, Chicago, Illinois 60612, USA
J Virol 77:5829-36. 2003..The capture of this configuration of Env could yield a suitable antigen for vaccine development, and it may also be a target for pharmacological intervention against HIV-1 entry...
- Pharmacokinetics of sifuvirtide, a novel anti-HIV-1 peptide, in monkeys and its inhibitory concentration in vitroShu jia Dai
Laboratory of Metabolism of Biotechnology Derived Drugs, Beijing Institute of Radiation Medicine, Beijing 100850, China
Acta Pharmacol Sin 26:1274-80. 2005..To study the pharmacokinetics of sifuvirtide, a novel anti-human immunodeficiency virus (HIV) peptide, in monkeys and to compare the inhibitory concentrations of sifuvirtide and enfuvirtide on HIV-1-infected-cell fusion...
- A V3 loop-dependent gp120 element disrupted by CD4 binding stabilizes the human immunodeficiency virus envelope glycoprotein trimerShi Hua Xiang
Dana Farber Cancer Institute, 44 Binney Street, CLS 1010, Boston, MA 02115, USA
J Virol 84:3147-61. 2010..CD4 binding dismantles this element, altering the gp120-gp41 relationship and rendering the hydrophobic patch in the V3 tip available for chemokine receptor binding...
- Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41M B Zwick
Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA
J Virol 75:10892-905. 2001..g., subtypes B, C, and E). The results suggest that a rather extensive region of gp41 close to the transmembrane domain is accessible to neutralizing Abs and could form a useful target for vaccine design...
- Structure-guided alterations of the gp41-directed HIV-1 broadly neutralizing antibody 2F5 reveal new properties regarding its neutralizing functionJavier Guenaga
IAVI Neutralizing Antibody Center at The Scripps Research Institute, La Jolla, California, United States of America
PLoS Pathog 8:e1002806. 2012..The data suggest a new mechanism of action, important for vaccine design, in which the 2F5 CDRH3 contacts and destabilizes the MPER helix downstream of its core epitope to allow induction of the extended-loop conformation...
- Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding siteJean Philippe Julien
Department of Biochemistry, University of Toronto, 1 King s College Circle, Toronto, Ontario, Canada M5S 1A8
J Mol Biol 384:377-92. 2008....
- Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challengesMorgane Bomsel
Mucosal Entry of HIV 1 and Mucosal Immunity, Cell Biology and Host Pathogen Interactions Department, Cochin Institute, CNRS UMR 8104, 22 rue Mechain, Paris, France
Immunity 34:269-80. 2011..The protection observed challenges the paradigm whereby circulating antiviral antibodies are required for protection against HIV-1 infection and may serve in designing a human vaccine against HIV-1-AIDS...
- Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirionsJames M Binley
Departments of Immunology and Molecular Biology, The Scripps Research Institute, La Jolla, California 92037, USA
J Virol 77:5678-84. 2003..Overall, this disulfide-shackled virus is a unique tool with potential utility in vaccine design, drug discovery, and elucidation of the HIV-1 entry process...
- Maturation-induced cloaking of neutralization epitopes on HIV-1 particlesAmanda S Joyner
Department of Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
PLoS Pathog 7:e1002234. 2011..Masking of neutralization-sensitive epitopes during particle maturation may contribute to HIV-1 immune evasion and has practical implications for vaccine strategies targeting the gp41 MPER...
- The cytoplasmic domain of the HIV-1 glycoprotein gp41 induces NF-κB activation through TGF-β-activated kinase 1Thomas S Postler
New England Primate Research Center, Department of Microbiology and Molecular Genetics, Harvard Medical School, Southborough, MA 01772 9102, USA
Cell Host Microbe 11:181-93. 2012..These findings demonstrate an evolutionarily conserved role for gp41CD in activating NF-κB to promote infection...
- Small molecules that bind the inner core of gp41 and inhibit HIV envelope-mediated fusionGary Frey
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, 250 Longwood Avenue, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 103:13938-43. 2006..They bind in a highly conserved, hydrophobic pocket on the inner core of the gp41 trimer, a region previously identified as a potential inhibitor site...
- Structural basis of HIV-1 neutralization by affinity matured Fabs directed against the internal trimeric coiled-coil of gp41Elena Gustchina
Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
PLoS Pathog 6:e1001182. 2010....
- Impact of the HIV-1 env genetic context outside HR1-HR2 on resistance to the fusion inhibitor enfuvirtide and viral infectivity in clinical isolatesFranky Baatz
Laboratory of Retrovirology, CRP Sante, Luxembourg, Luxembourg
PLoS ONE 6:e21535. 2011....
- Crystallographic definition of the epitope promiscuity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5: vaccine design implicationsSteve Bryson
Department of Biochemistry, University of Toronto, 1 King s College Circle, Toronto, Ontario, Canada M5S 1A8
J Virol 83:11862-75. 2009..Based on our results, we propose a somewhat more flexible molecular model of epitope recognition by bnMAb 2F5, which could guide future attempts at designing small-molecule MPER-like vaccines capable of eliciting 2F5-like antibodies...
- Highly conserved structural properties of the C-terminal tail of HIV-1 gp41 protein despite substantial sequence variation among diverse clades: implications for functions in viral replicationJonathan D Steckbeck
Center for Vaccine Research, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, USA
J Biol Chem 286:27156-66. 2011....
- Role of HIV membrane in neutralization by two broadly neutralizing antibodiesS Munir Alam
Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA
Proc Natl Acad Sci U S A 106:20234-9. 2009..These results bear directly on strategies for rational design of HIV-1 envelope immunogens...
- Maturation-dependent human immunodeficiency virus type 1 particle fusion requires a carboxyl-terminal region of the gp41 cytoplasmic tailJiyang Jiang
Department of Microbiology and Immunology, Vanderbilt University School of Medicine, A 5301 Medical Center North, Nashville, TN 37232 2363, USA
J Virol 81:9999-10008. 2007..They further indicate that the stable association of gp41 with Gag in immature virions is not sufficient for inhibition of immature HIV-1 particle fusion...
- HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysisD Tudor
Entrée Muqueuse du VIH et Immunité Muqueuse, Mucosal Entry of HIV 1 and Mucosal Immunity, Departement de Biologie Cellulaire, Cell Biology Department, Institut Cochin, Universite Paris Descartes, CNRS UMR 8104, Paris, France
Mucosal Immunol 2:412-26. 2009..This analysis of HEPS monoclonal IgA gives a unique opportunity to correlate an antibody function (resistance to a pathogen in vivo) with an antibody gene. Such neutralizing monoclonal IgAs could be used in microbicide formulation...
- Novel recombinant engineered gp41 N-terminal heptad repeat trimers and their potential as anti-HIV-1 therapeutics or microbicidesXi Chen
School of Life Sciences, Tsinghua University, Beijing 100084, China
J Biol Chem 285:25506-15. 2010..Therefore, N28Fd trimer has great potentials for further development as an affordable therapeutic or microbicide for treatment and prevention of HIV-1 infection...
- NK cytotoxicity against CD4+ T cells during HIV-1 infection: a gp41 peptide induces the expression of an NKp44 ligandVincent Vieillard
Laboratoire d Immunologie Cellulaire et Tissulaire, Institut National de la Sante et de la Recherche Medicale U543, Hopital Pitie Salpetriere, 75013 Paris, France
Proc Natl Acad Sci U S A 102:10981-6. 2005..Understanding this mechanism may help to develop future therapeutic strategies and vaccines against HIV-1 infection...
- Regulation of human immunodeficiency virus type 1 Env-mediated membrane fusion by viral protease activityTsutomu Murakami
Department of Immunology, Graduate School and Faculty of Medicine, University of the Ryukyus, Nishihara, Okinawa 903 0215, Japan
J Virol 78:1026-31. 2004..Interestingly, truncation of the gp41 cytoplasmic tail reversed the fusion defect. These results suggest that interactions between unprocessed Gag and the gp41 cytoplasmic tail suppress fusion...
- Crystal structure and size-dependent neutralization properties of HK20, a human monoclonal antibody binding to the highly conserved heptad repeat 1 of gp41Charles Sabin
Unit of Virus Host Cell Interactions, UMI 3265, Université Joseph Fourier EMBL CNRS, Grenoble, France
PLoS Pathog 6:e1001195. 2010....
- Interaction of endocytic signals from the HIV-1 envelope glycoprotein complex with members of the adaptor medium chain familyH Ohno
Cell Biology and Metabolism Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892, USA
Virology 238:305-15. 1997..These observations suggest that HIV-1 Env utilizes the protein sorting machinery of the host cells for internalization and sorting at various steps of the endocytic and biosynthetic pathways...
- Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivityB K Chakrabarti
IAVI Neutralizing Antibody Center at TSRI, The Scripps Research Institute, La Jolla, CA 92037, USA
J Virol 85:8217-26. 2011....
- A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1G Stiegler
Institute of Applied Microbiology, University of Agricultural Sciences, A 1190 Vienna, Austria
AIDS Res Hum Retroviruses 17:1757-65. 2001..Moreover, our results suggest that 4E10 should be further investigated for passive anti-HIV immunotherapy...
- Broadly neutralizing anti-HIV-1 antibodies disrupt a hinge-related function of gp41 at the membrane interfaceLikai Song
Cancer Vaccine Center, Dana Farber Cancer Institute, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 106:9057-62. 2009..HIV-1 MPER features important for targeted vaccine design have been revealed, the implications of which extend to BNAb targets on other viral fusion proteins...
- Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41Cleo G Anastassopoulou
Department of Microbiology and Immunology, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021, USA
Proc Natl Acad Sci U S A 106:5318-23. 2009..Together, the experimental results and theoretical model may help understand how HIV-1 uses CCR5 to enter target cells under various conditions...
- A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodiesGary Frey
Laboratory of Molecular Medicine, Children s Hospital, and Department of Pediatrics, Harvard Medical School, 320 Longwood Avenue, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 105:3739-44. 2008..These results help explain the rarity of 2F5- and 4E10-like antibody responses and suggest a strategy for eliciting them...
- In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadthXiaoying Shen
Duke Human Vaccine Institute, Duke University Medicine Center, Durham, NC 27710, USA
J Virol 83:3617-25. 2009..Our findings suggest that multiple events (i.e., genetic predisposition and HIV-1 immune dysregulation) may be required for induction of broadly reactive gp41 MPER antibodies in natural infection...
- Single-particle cryoelectron microscopy analysis reveals the HIV-1 spike as a tripod structureShang Rung Wu
Department of Biosciences and Nutrition, Karolinska Institute, S 141 83 Huddinge, Sweden
Proc Natl Acad Sci U S A 107:18844-9. 2010..The loop displacements probably prepared the spike for coreceptor interaction and roof opening so that a new fusion-active gp41 structure, assembled at the center of the cage bottom, could reach the target membrane...
- Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitutionXiaoying Shen
Department of Surgery, Duke Human Vaccine Institute, Duke University, Durham, NC 27710, USA
Proc Natl Acad Sci U S A 107:5972-7. 2010..These data suggest that a major contribution to the L669S mutant virus phenotype of enhanced susceptibility to MPER mAbs is prolonged exposure of the MPER neutralizing epitope during viral entry...
- Electron tomography of the contact between T cells and SIV/HIV-1: implications for viral entryRachid Sougrat
Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America
PLoS Pathog 3:e63. 2007..Determination of the molecular composition and structure of the entry claw may facilitate the identification of improved drugs for the inhibition of HIV-1 entry...
- Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion stateMikyung Kim
Laboratory of Immunobiology, Department of Medical Oncology, Dana Farber Cancer Institute and Department of Medicine, Harvard Medical School, Boston, MA 02115, United States
Vaccine 25:5102-14. 2007..In addition, the anti-gp41 immune response was preferentially directed to the C-helical domain, away from the MPER. Future vaccine design needs to contend with the complexity of epitope display as well as immunodominance...
- Endocytosis of endogenously synthesized HIV-1 envelope protein. Mechanism and role in processing for association with class II MHCJ F Rowell
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
J Immunol 155:473-88. 1995....
- The membrane-proximal tryptophan-rich region of the HIV glycoprotein, gp41, forms a well-defined helix in dodecylphosphocholine micellesD J Schibli
Department of Biological Sciences, University of Calgary, Alberta, Canada
Biochemistry 40:9570-8. 2001..This work shows that the Trp-rich membrane-proximal region of HIV and related viruses can bind to the surfaces of zwitterioninc membranes in a "Velcro-like" manner...
- Role of hydrophobic residues in the central ectodomain of gp41 in maintaining the association between human immunodeficiency virus type 1 envelope glycoprotein subunits gp120 and gp41Joanne York
Montana Biotechnology Center, The University of Montana, Missoula, Montana 59812, USA
J Virol 78:4921-6. 2004..These envelope glycoproteins readily shed their gp120 and are unable to mediate cell-cell fusion. These findings suggest an important role for the conserved bulky hydrophobic residues in stabilizing the gp120-gp41 complex...
- In vivo efficacy of anti-glycoprotein 41, but not anti-glycoprotein 120, immunotoxins in a mouse model of HIV infectionSeth H Pincus
Department of Microbiology and Animal Resources Center, Montana State University, Bozeman, MT 59717, USA
J Immunol 170:2236-41. 2003..These data support continued exploration of the utility of ITs for HIV infection, particularly the use of anti-gp41 ITs in combination with soluble CD4 derivatives...
- Monoclonal antibodies that bind to the core of fusion-active glycoprotein 41C H Chen
Department of Microbiology, Meharry Medical College, Nashville, Tennessee 37208, USA
AIDS Res Hum Retroviruses 16:2037-41. 2000..Antibodies that are able to interact with the core of the putative fusion-active gp41 may be useful in further unveiling the mechanism of HIV-induced membrane fusion...
- Coreceptor tropism can be influenced by amino acid substitutions in the gp41 transmembrane subunit of human immunodeficiency virus type 1 envelope proteinWei Huang
Monogram Biosciences, 345 Oyster Point Blvd, South San Francisco, CA 94080, USA
J Virol 82:5584-93. 2008..We hypothesize that the latter plays an important role in the transition from CCR5 to CXCR4 coreceptor use...
- Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociationP Poignard
Centre d immunologie de Marseille Luminy, France
J Exp Med 183:473-84. 1996....
- HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cellsJennifer M Pfaff
Department of Microbiology, University of Pennsylvania, 3610 Hamilton Walk, Philadelphia, PA 19104, USA
J Virol 84:6505-14. 2010....
- Membrane expression of HIV envelope glycoproteins triggers apoptosis in CD4 cellsA G Laurent-Crawford
Institut Pasteur, Department of AIDS and Retroviruses, UA CNRS 1157, Paris, France
AIDS Res Hum Retroviruses 9:761-73. 1993..Therefore, cell death during HIV infection in CD4+ lymphocyte cultures is due to a specific event triggered by the gp120-gp41 heterodimer complex programming death in metabolically active cells...
- Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particlesS Phogat
Structural Virology Section, Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892 3005, USA
Virology 373:72-84. 2008..The first generation HBsAg-MPER particles represent a unique means to present HIV-1 envelope glycoprotein neutralizing determinants to the immune system...
- HIV-1 neutralization: mechanisms and relevance to vaccine designMichael B Zwick
Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA
Curr HIV Res 5:608-24. 2007....
- Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infectionS Munir Alam
Human Vaccine Institute, Box 3258, Duke University Medical Center, MSRBII Bldg, Room 4042, Durham, NC 27710, USA
J Virol 82:115-25. 2008....
- Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particlesHongtao Zhang
Department of Microbiology and Immunology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA
J Virol 78:8342-8. 2004..Importantly, the sera and fecal extracts from mice orally immunized with the CVLPs neutralized HIV-1(MN) in vitro. Thus, BPV-HIV-1 gp41 CVLPs may be used to prevent and to treat HIV-1 infection...
- Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatmentStefano Menzo
Istituto di Microbiologia e Scienze Biomediche, Universita Politecnica delle Marche, Ancona, Italy
Antimicrob Agents Chemother 48:3253-9. 2004....
- In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1Daniel P Leaman
Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA
J Virol 84:3382-95. 2010..Heterogeneity in Env from endogenous and exogenous sources might also subvert humoral immunity to HIV-1, so in-solution VCAs may help to dissect this heterogeneity for vaccine design purposes...
- Induction of neutralizing antibody against human immunodeficiency virus type 1 (HIV-1) by immunization with gp41 membrane-proximal external region (MPER) fused with porcine endogenous retrovirus (PERV) p15E fragmentMin Luo
Department of Cell Biology and Genetics, The College of Life Sciences, No 5 Yi He Yuan Road, Peking University, Beijing 100871, China
Vaccine 24:435-42. 2006..These results offer a new strategy for HIV-1 vaccine design and development targeting the gp41 MPER...
- Depletion of latent HIV-1 infection in vivo: a proof-of-concept studyGinger Lehrman
University of Texas Southwestern Medical Center at Dallas, Department of Medicine, Division of Infectious Diseases, 5323 Harry Hines Boulevard, Dallas, TX 753901, USA
Lancet 366:549-55. 2005..Since the chromatin remodeling enzyme histone deacetylase 1 (HDAC1) maintains latency of integrated HIV, we tested the ability of the HDAC inhibitor valproic acid to deplete persistent, latent infection in resting CD4+ T cells...
- Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodiesGary Frey
Division of Molecular Medicine, Children s Hospital, Harvard Medical School, Boston, Massachusetts, USA
Nat Struct Mol Biol 17:1486-91. 2010..These results have important implications for gp41-based vaccine design...
- Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitorsDirk Eggink
Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam, Academic Medical Center of the University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
J Biol Chem 284:26941-50. 2009..Implications for the design of novel antiviral peptide inhibitors are discussed...
- Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjectsD Noah Sather
Seattle Biomedical Research Institute, Seattle, WA 98109, United States
Vaccine 28:B8-12. 2010..Overall, our study indicates that more than one pathway leads to the development of broad cross-reactive NAbs during HIV-infection...
- Structural characterization of HIV gp41 with the membrane-proximal external regionWuxian Shi
Center for Synchrotron Biosciences, Case Western Reserve University, Cleveland, OH 44106, USA
J Biol Chem 285:24290-8. 2010....
- Neutralizing as well as non-neutralizing polyclonal immunoglobulin (Ig)G from infected patients capture HIV-1 via antibodies directed against the principal immunodominant domain of gp41Renaud Burrer
EA3770, Institut de Virologie, Universite Louis Pasteur, 67000 Strasbourg, France
Virology 333:102-13. 2005..Thus, capture assays, including the immune complex capture assay that is more representative of "physiological" conditions, cannot be used as surrogate method for the investigation of the neutralizing activity of Abs...
- Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodiesS Gnanakaran
Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, New Mexico, USA
PLoS Comput Biol 6:e1000955. 2010..Five sites were in the CD4-induced coreceptor binding site of gp120, suggesting an important role for this region in the elicitation of broadly neutralizing antibody responses against HIV-1...
- Characterization of a trimeric MPER containing HIV-1 gp41 antigenAndreas Hinz
Unit for Virus Host Cell Interaction, UMI 3265 UJF EMBL CNRS, 6 rue Jules Horowitz, 38042 Grenoble Cedex 9, France
Virology 390:221-7. 2009..Thus trimerisation of MPER regions does not suffice to induce a potent neutralizing antibody response specific for conserved regions within gp41...
- A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individualsLaura M Walker
Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America
PLoS Pathog 6:e1001028. 2010..In approximately half of the donors, key N-linked glycans were critical for expression of the epitopes recognized by the bNAb specificities in the sera...
- Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and CJames M Binley
Torrey Pines Institute for Molecular Studies, 3550 General Atomics Court, San Diego, California 92121, USA
J Virol 82:11651-68. 2008....
- Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external regionElin S Gray
AIDS Virus Research Unit, National Institute for Communicable Diseases, Johannesburg, South Africa
J Virol 83:11265-74. 2009..Nevertheless, the identification of three novel antibody specificities within the MPER supports its further study as a promising target for vaccine design...
- Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1Michael B Zwick
Department of Immunology IMM 2, The Scripps Research Institute, 10550 North Torrey Pines Rd, La Jolla, CA 92037, USA
J Virol 79:1252-61. 2005..Neutralization experiments showing synergy between and T20 and 4E10 against HIV-1 are also presented. The data presented may aid in the design of antigens that better present the MPER of gp41 to the immune system...
Research Grants151 found, 100 shown here
- Preventing the Establishment of Enfuvirtide-resistance in the Latent ReservoirSteven Deeks; Fiscal Year: 2007..Also, we believe that insights regarding the mechanisms operative in elite controllers will prove to be highly informative for future efforts aimed at preventing HIV infection and eradicating virus in those already infected. ..
- Coreceptor Modulation of TCR-MHC InteractionsS Alam; Fiscal Year: 2003..abstract_text> ..
- SARS-CoV S Protein Receptor-binding Domain-based VaccinesShibo Jiang; Fiscal Year: 2010..The long-term goal of this project is to develop highly effective and safe subunit vaccines for protecting at-risk populations from SARS-CoV infection or bioterrorism attack. ..
- Rational Design of HIV Fusion Inhibitors Targeting gp41Shibo Jiang; Fiscal Year: 2007..Therefore, this research is relevant to public health. ..
- RATIONAL DESIGN OF ANTIVIRAL COMPOUNDS TO THE GP41 COREShibo Jiang; Fiscal Year: 2003..The long-term goal is to develop novel anti-HIV-1 drugs for chemotherapy of HIV-1 infection and AIDS. ..
- SARS-CoV S Protein Receptor-binding Domain-based VaccinesShibo Jiang; Fiscal Year: 2009..The long-term goal of this project is to develop highly effective and safe subunit vaccines for protecting at-risk populations from SARS-CoV infection or bioterrorism attack. ..
- SARS-CoV S Protein Receptor-binding Domain-based VaccinesShibo Jiang; Fiscal Year: 2007..The long-term goal of this project is to develop highly effective and safe subunit vaccines for protecting at-risk populations from SARS-CoV infection or bioterrorism attack. ..
- Rational Design of HIV Fusion Inhibitors Targeting gp41Shibo Jiang; Fiscal Year: 2009..Therefore, this research is relevant to public health. ..
- Multivalent gp41 Peptides as Novel ImmunogensLai Xi Wang; Fiscal Year: 2004..The structure-immunogenicity relationships will be evaluated. It is expected that the proposed studies will yield important new data with significant relevance to the development of an effective HIV-1 vaccine. ..
- Novel Vaccine Targeting the Sugar Coat of HIV-1Lai Xi Wang; Fiscal Year: 2004..The synthetic conjugate-vaccine will be used to immunize mice. The immune responses will be analyzed using ELISAs and virus neutralization assays. ..
- NEUTRALIZING ANTIBODIES AGAINST ORTHOPOX VIRUSESDennis Burton; Fiscal Year: 2004..To examine the impact of passive immunization in immunoprophylaxis and immunotherapy of a smallpox-like disease in a non-human primate model, we will use an experimental model of monkeypox virus infection ..
- THE ANTIVIRAL ACTIVITY OF ANTIBODIES TO A FILOVIRUSDennis Burton; Fiscal Year: 2004....
- ANTIBODIES AGAINST HIV-1 gp41: TOOLS FOR VACCINE DESIGNMichael Zwick; Fiscal Year: 2005..A panel of mAbs against the described epitopes on gp41 will provide valuable tools to aid in HIV-1 vaccine design. ..
- Enzymatic Transglycosylation for N-Glycopeptide SynthesisLai Xi Wang; Fiscal Year: 2007..In the long term, the proposed studies will contribute to the development of glycoprotein-based drugs. ..
- Convergent Chemoenzymatic Synthesis of Glycopeptides and GlycoproteinsLai Xi Wang; Fiscal Year: 2007..The knowledge gained from the proposed research will eventually facilitate the development of glycoprotein-based therapeutics. ..
- ANTIBODY EFFECTOR FUNCTION IN PROTECTION AGAINST HIV-1Dennis Burton; Fiscal Year: 2007..The results will help clarify how antibodies protect against HIV and may have implications for vaccine design and microbicide development. ..
- IMMUNOFOCUSING TO A NEUTRALIZING EPITOPE ON GP120Dennis Burton; Fiscal Year: 2007..Immunization with this molecule should, in principle, be akin to immunizing with the footprint of b12. ..
- HIV-1 Glycopeptides as ImmunogensLai Xi Wang; Fiscal Year: 2007..The proposed research attempts to raise broadly neutralizing antibodies through novel immunogen design. The research will yield important new data with direct relevance to HIV-1 vaccine development. ..
- Targeting neutralizing antibody-defined sites on HIV gp41 for vaccine designMichael Zwick; Fiscal Year: 2007..In these ways, antibody access to the MPER and NHR region of gp41 will be precisely evaluated, which in turn should lead to improved gp41-based immunogens that will elicit more potent neutralizing Abs against HIV-1. ..
- HUMAN ANTIBODIES TO HIV-1 BY REPERTOIRE CLONINGDennis Burton; Fiscal Year: 2007..This project aims to understand how to best trigger a neutralizing antibody response to HIV. There is widespread agreement that an HIV vaccine will need to trigger such a response to be fully effective. ..
- COOPERATIVE HUMORAL & CELLULAR IMMUNITY AGAINST HIV/SIVDennis Burton; Fiscal Year: 2005..This will provide us with the first opportunity to look at the effects of potent human mAbs on established infection in the presence of functional T cells. ..
- VIRAL EVASION AND HIV ENTRY-BLOCKING STRATEGIESDennis Burton; Fiscal Year: 2004..The studies will reveal how HIV-1 can evade entry-blocking strategies, and may provide important information for vaccine design. ..
- HUMAN ANTIBODIES TO HIV-1 BY REPERTOIRE CLONINGDennis Burton; Fiscal Year: 2009..Both aims are focused on providing the tools that will eventually allow us to generate or design immunogens that reliably elicit broadly neutralizing Abs. ..
- HUMAN ANTIBODIES TO HIV-1 BY REPERTOIRE CLONINGDennis Burton; Fiscal Year: 1993..The research will provide opportunities to explore the mechanism(s) responsible for virus neutralization and some of the rules governing antibody recognition of viral antigens...
- Probing the antibody response to HCV to facilitate rational immunogen designDennis R Burton; Fiscal Year: 2010..We propose to develop antibody-inducing vaccine candidates against HCV. A key feature of our work is the rational design of vaccine candidates based on countering some of the tricks that this virus uses to evade antibodies. ..
- Targeting neutralizing antibody-defined sites on HIV gp41 for vaccine designMichael B Zwick; Fiscal Year: 2010..In these ways, antibody access to the MPER and NHR region of gp41 will be precisely evaluated, which in turn should lead to improved gp41-based immunogens that will elicit more potent neutralizing Abs against HIV-1. ..
- THE HUMAN ANTIBODY RESPONSE TO METAPNEUMOVIRUS: PROPHYLAXIS AND VACCINE DESIGNDennis R Burton; Fiscal Year: 2010..Such antibodies will be positioned for immediate clinical development as passive prophylactic agents for the prevention of HMPV disease in vulnerable patient cohorts. ..
- HUMAN ANTIBODIES TO HIV-1 BY REPERTOIRE CLONINGDennis R Burton; Fiscal Year: 2010..PUBLIC HEALTH RELEVANCE: An optimal HIV vaccine will likely elicit broadly neutralizing antibodies. This application seeks to understand broad neutralization at the molecular level to permit the design of such a vaccine. ..
- ANTI-HIV ANTIBODY IMMUNOTHERAPY IN HUPBL-SCIDDennis Burton; Fiscal Year: 2001..The emerging results should assist in the design of immunotherapeutic strategies using neutralizing antibodies and illuminate areas of potential concern such as neutralization escape. ..
- HIV-1 Gene Suppression by CD8+T CellGeorgia Tomaras; Fiscal Year: 2005..These studies will further our understanding of this potent means of virologic control and promote the development of this host cellular immune response in future therapeutic and vaccination strategies. ..
- UAB AIEDRP: Immune Control and Escape in Acute InfectionJOHN KILBY; Fiscal Year: 2006..Finally, our proposal involves collaborations with other AIEDRP units where an important exchange of patient specimens, scientific expertise, technology, and data will continue. ..
- NCRR FACSAria Cell SorterBarton Haynes; Fiscal Year: 2004..Advisory committees, institutional support, financial support for continued maintenance, and management plans are in place to insure that the instrument will be fully and appropriately utilized. ..
- ANTIGENIC PROPERTIES OF THE V1/V2 DOMAIN OF HIV-1 GP120Abraham Pinter; Fiscal Year: 2009....
- HIV-1 Glycopeptides as ImmunogensLai Xi Wang; Fiscal Year: 2009..Theproposed research attempts to raise broadly neutralizing antibodies through novel immunogen design. Theresearch willyield important new data with direct relevance to HIV-1 vaccine development. ..
- ANTIGENIC PROPERTIES OF THE V1/V2 DOMAIN OF HIV-1 GP120Abraham Pinter; Fiscal Year: 2010....
- Impact of maternal HAART on HIV-infected breastfeeding infants: MalawiSusan H Eshleman; Fiscal Year: 2010..We will determine whether initiation of treatment in breastfeeding women poses any risk to breastfeeding infants who are HIV-infected, by inducing resistance to antiretroviral drugs in the infant's virus. ..
- Long-Acting HIV Therapy for Injection Drug UsersJeffrey M Jacobson; Fiscal Year: 2010..We propose a novel treatment strategy involving systemic administration of long-acting antiretroviral therapy as a means to ensure effective drug delivery and viral suppression in HIV-infected populations prone to poor drug-adherence. ..
- Invasion of C. neoformans into brain endothelial cellsAmbrose Y Jong; Fiscal Year: 2010..neoformans internalizes into the HBMEC. The information derived from the studies is expected to be helpful in the development of novel strategies to prevent cryptococcal meningitis and its associated morbidity. ..
- CSF & Lymphocyte Dynamics in HIV InfectionRichard Price; Fiscal Year: 2009..Beyond its immediate implications for prevention, diagnosis and treatment of Neuro-AIDS, it bears on the understanding other immune, inflammatory and degenerative neurological diseases. ..
- Induction of HIV-specific Immune ResponsesRajesh T Gandhi; Fiscal Year: 2010..By understanding the mechanisms by which immune responses against HIV can be augmented, this may lead to improved ways of treating this disease and may help in developing a vaccine to prevent this infection. ..
- The impact of early antiretroviral therapy on HIV persistence and inflammationSTEVEN GRANT DEEKS; Fiscal Year: 2010..Our work may also provide important insights in the role of chronic inflammation in driving viral persistence, and hence may lead to the development of novel interventions. ..
- Structure, Assembly, and Function of Outer Membrane ProteinsLukas K Tamm; Fiscal Year: 2010..e. a clinically important pathogen in hospital-induced infections and complications of cystic fibrosis. The research may ultimately contribute to better treatments of these infections. ..
- ANTIGENIC PROPERTIES OF THE V1/V2 DOMAIN OF HIV-1 GP120Abraham Pinter; Fiscal Year: 2006....
- HIV Prevention Trials Network: Network LaboratorySusan Eshleman; Fiscal Year: 2007..Therefore, our agenda is complementary to long-term investments (finding a cure, vaccine, or microbicide). ..
- STRUCTURE AND FOLDING OF INTEGRAL MEMBRANE PROTEINSLUKAS TAMM; Fiscal Year: 2004..abstract_text> ..